Antiphosphatidylethanolamine antibody as a marker of antiphospholipid syndrome?;Anticorps antiphosphatidyléthanolamine, un marqueur du syndrome des antiphospholipides ?

Presse Medicale

Volumn 44, Issue 3, 2015, Pages 284-291

  Yelnik, Cécile Marie ^a   Dubucquoi, Sylvain ^a   Houfflin Debarge, Véronique ^a   Lambert, Marc ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PHOSPHATIDYLETHANOLAMINE ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PHOSPHATIDYLETHANOLAMINE;

ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; DISEASE MARKER; FEMALE; HUMAN; PREGNANCY COMPLICATION; RISK ASSESSMENT; SHORT SURVEY; THROMBOSIS; BLOOD; IMMUNOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; FEMALE; HUMANS; PHOSPHATIDYLETHANOLAMINES; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

EID: 84924483047     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.06.033     Document Type: Short Survey

References (33)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. Nayfe R., Uthman I., Aoun J., Saad Aldin E., Merashli M., Khamashta M.A. Seronegative antiphospholipid syndrome. Rheumatology 2013, 52:1358-1367.
3. Bertolaccini M.L., Amengual O., Atsumi T., Binder W.L., de Laat B., Forastiero R., et al. Non-criteria" aPL tests: report of a task force and preconference workshop. Lupus 2011, 20:191-205.
4. Staub H.L., Harris E.N., Khamashta M.A., Savidge G., Chahade W.H., Hughes G.R. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis 1989, 48:166-169.
5. Zhixin Li, Wells C.W., North P.E., Kumar S., Duris C.B., McIntyre J.A., et al. Phosphatidylethanolamine at the luminal endothelial surface-implications for hemostasis and thrombotic autoimmunity. Clin Appl Thromb Hemost 2011, 17:158-163.
6. Sugi T., McIntyre J.A. Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens. J Autoimmun 2001, 17:207-214.
7. Smirnov M.D., Ford D.A., Esmon C.T., Esmon N.L. The effect of membrane composition on the hemostatic balance. Biochemistry 1999, 38:3591-3598.
8. Baumgärtner P., Geiger M., Zieseniss S., Malleier J., Huntington J.A., Hochrainer K., et al. Phosphatidylethanolamine critically supports internalization of cell-penetrating protein C inhibitor. J Cell Biol 2007, 179:793-804.
9. Tian Y., Jackson P., Gunter C., Wang J., Rock C.O., Jackowski S. Placental thrombosis and spontaneous fetal death in mice deficient in ethanolamine kinase 2. J Biol Chem 2006, 281:28438-28449.
10. Velayuthaprabhu S., Matsubayashi H., Sugi T., Nakamura M., Ohnishi Y., Ogura T., et al. A unique preliminary study on placental apoptosis in mice with passive immunization of antiphosphatidylethanolamine antibodies and anti-factor XII antibodies. Am J Reprod Immunol 2011, 66:373-384.
11. Sugi T., McIntyre J.A. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995, 86:3083-3089.
12. Sanmarco M., Bardin N. The contribution of antiphosphatidylethanolamine antibodies in the diagnosis of the antiphospholipid syndrome. Lupus 2012, 21:727-728.
13. McIntyre J.A., Wagenknecht D.R. Antiphosphatidylethanolamine (aPE) antibodies: a survey. J Autoimmun 2000, 15:185-193.
14. Berard M., Boffa M.C. Influence of the phosphatidylethanolamine (PE) and bovine serum origins on anti-PE antibody detection by ELISA. Thromb Res 1997, 85:439-442.
15. Obayashi S., Ozaki Y., Sugi T., Kitaori T., Katano K., Suzuki S., et al. Antiphosphatidylethanolamine antibodies might not be an independent risk factor for further miscarriage in patients suffering recurrent pregnancy loss. J Reprod Immunol 2010, 85:186-192.
16. Sanmarco M. ELISA for antiphosphatidylethanolamine antibody detection: high impact of assay buffer on results. J Immunol Methods 2010, 358:9-16.
17. Gris J.C., Quéré I., Sanmarco M., Boutiere B., Mercier E., Amiral J., et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nîmes Obstetricians and Haematologists Study-NOHA. Thromb Haemost 2000, 84:228-236.
18. Sugi T., Katsunuma J., Izumi S., McIntyre J.A., Makino T. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril 1999, 71:1060-1065.
19. Sugi T., Matsubayashi H., Inomo A., Dan L., Makino T. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res 2004, 30:326-332.
20. Yamada H., Atsumi T., Kobashi G., Ota C., Kato E.H., Tsuruga N., et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009, 79:188-195.
21. Balada E., Ordi-Ros J., Paredes F., Villarreal J., Mauri M., Vilardell-Tarrés M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol 2001, 30:235-241.
22. Matsubayashi H., Sugi T., Arai T., Kondo A., Suzuki T., Izumi S., et al. Different antiphospholipid antibody specificities are found in association with early repeated pregnancy loss versus recurrent IVF-failure patients. Am J Reprod Immunol 2001, 46:323-329.
23. Ulcova-Gallova Z., Krauz V., Novakova P., Milichovska L., Micanova Z., Bibkova K., et al. Antiphospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only. Am J Reprod Immunol 2005, 54:112-117.
24. Karmochkine M., Cacoub P., Piette J.C., Godeau P., Boffa M.C. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheumatol 1992, 10:603-605.
25. Karmochkine M., Berard M., Piette J.C., Cacoub P., Aillaud M.F., Harlé J.R., et al. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus. Lupus 1993, 2:157-160.
26. Bertolaccini M.L., Murru V., Sciascia S., Sanna G., Khamashta M.A. The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE). Thromb Res 2012, 130:914-918.
27. Bertolaccini M.L., Roch B., Amengual O., Atsumi T., Khamashta M.A., Hughes G.R. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol 1998, 37:1229-1232.
28. Gonzales-Portillo F., McIntyre J.A., Wagenknecht D.R., Williams L.S., Bruno A., Biller J. Spectrum of antiphospholipid antibodies (aPL) in patients with cerebrovascular disease. J Stroke Cerebrovasc 2001, 10:222-226.
29. Sanmarco M., Alessi M.C., Harle J.R., Sapin C., Aillaud M.F., Gentile S., et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost 2001, 85:800-805.
30. Sanmarco M., Gayet S., Alessi M.-C., Audrain M., de Maistre E., Gris J.-C., et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007, 97:949-954.
31. Hirmerova J., Ulcova-Gallova Z., Seidlerova J., Filipovsky J., Bibkova K., Micanova Z., et al. Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism. Clin Appl Thromb Hemost 2010, 16:318-325.
32. Hughes G.R., Khamashta M.A. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003, 62:1127.
33. Rodriguez-Garcia J.L., Bertolaccini M.L., Cuadrado M.J., Sanna G., Ateka-Barrutia O., Khamashta M.A. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called "seronegative APS"). Ann Rheum Dis 2012, 71:242-244.